Turbulent flow and ternary column-switching on-line clean-up system for high-throughput quantification of risperidone and its main metabolite in plasma by LC-MS/MS - Application to a bioequivalence study

被引:22
作者
Kousoulos, Constantinos
Dotsikas, Yannis
Loukas, Yannis L. [1 ]
机构
[1] Univ Athens, Lab Pharmaceut Anal, Dept Pharmaceut Chem, Sch Pharm, GR-15771 Athens, Greece
[2] Univ Athens, Bioequivalence Serv GLP Compliant, Dept Pharmaceut Chem, Sch Pharm, GR-15771 Athens, Greece
关键词
Risperidone; column-switching; mass spectrometry; 96-well; sub-zero extraction; bioequivalence; TANDEM MASS-SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; SOLID-PHASE EXTRACTION; QUANTITATIVE-DETERMINATION; ALPHA(V)BETA(3) ANTAGONIST; ELECTROCHEMICAL DETECTION; SCHIZOPHRENIC-PATIENTS; LINEAR-REGRESSION; HUMAN SERUM; 9-HYDROXYRISPERIDONE;
D O I
10.1016/j.talanta.2006.10.049
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A high-throughput LC-MS/MS method was developed for the simultaneous determination of Risperidone and 9-OH-risperidone in human plasma. A semi-automated sample preparation procedure was applied, including protein precipitation after addition of ACN, via a robotic system, and subsequent sub-zero temperature extraction of the latter. Injections of the ACN extractants were performed on a turbulent flow ternary column-switching system, consisted of dual extraction columns in parallel for on-line purification of samples and an analytical column. Toggling with the assistance of two valves provided a run cycle time of 3 min and the whole procedure minimized carry-over effect. On-line clean-up procedure along with sub-zero temperature extraction increased sample purification and extended column life. The analytical range of the method was 0.1-200 ng mL(-1) for both analytes with excellent linearity and very good accuracy and precision. The proposed method was employed in a bioequivalence study after per os administration of a 2 mg tablet of risperidone and allowed the completion of the study (> 1400 samples) in only 4 days time. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:360 / 367
页数:8
相关论文
共 41 条
[1]   Model validation through the linear regression fit to actual versus predicted values [J].
Analla, M .
AGRICULTURAL SYSTEMS, 1998, 57 (01) :115-119
[2]  
Aravagiri M, 2000, J MASS SPECTROM, V35, P718, DOI 10.1002/1096-9888(200006)35:6<718::AID-JMS999>3.0.CO
[3]  
2-O
[4]   Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: Simultaneous determination by a high performance liquid chromatography with electrochemical detection [J].
Aravagiri, M ;
Marder, SR ;
Wirshing, D ;
Wirshing, WC .
PHARMACOPSYCHIATRY, 1998, 31 (03) :102-109
[5]   Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection [J].
Avenoso, A ;
Facciolà, G ;
Salemi, M ;
Spina, E .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2000, 746 (02) :173-181
[6]   Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction [J].
Barattè, S ;
Sarati, S ;
Frigerio, E ;
James, CA ;
Ye, C ;
Zhang, Q .
JOURNAL OF CHROMATOGRAPHY A, 2004, 1024 (1-2) :87-94
[7]   Quantitative determination of paclitaxel in human plasma using semi-automated liquid-liquid extraction in conjunction with liquid chromatography/tandem mass spectrometry [J].
Basileo, G ;
Breda, M ;
Fonte, G ;
Pisano, R ;
James, CA .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 32 (4-5) :591-600
[8]   Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia [J].
Chouinard, G ;
Kopala, L ;
Labelle, A ;
Beauclair, L ;
Johnson, SV ;
Singh, KI .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1998, 43 (10) :1018-1025
[9]  
CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25
[10]  
CHOUINARD G, 1993, CAN J PSYCHIAT, V38, P89